- Email: [email protected]
Call For Abstracts 18th Annual Meeting Cincinnati, Ohio May 24–26, 1988
BRIEF SUMMARY r
SILVADENE®CREAM (1% silver sulfadiazine)
Each gram of SILVADENE Cream contains 10 m g of micronized silver sulfadiazine. The cream vehicle consists of white petrolatum, stearyl alcohol, isopropyl myristate, sorbitan monooleate, polyoxyl 40 stearate, propylene glycol, and water, with methylparaben 0.3% as a preservative. Indications: Topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. C o n t r a i a d i c a t i o n s : Because sulfonamide therapy is known to increase the possibility of kernicterus, SILVADENE Cream should not be used at term pregnancy, on premature infants, or on newborn infants during the first month of life. Warnings: SILVADENE Cream should be administered with great caution to patients with history of hypersensitivity to SILVADENE Cream. It is not known whether there is cross-sensitivity to other sulfonamides. If allergic reactions attributable to treatment with SILVADENE Cream occur, discontinuation of SILVADENE Cream must be considered. The use of SILVADENE Cream in some cases of glucose-6-phosphate dehydrogenase deficient individuals may be hazardous, as hemolysis may occur. USE IN PREGNANCY. Safe use of SILVADENE Cream during pregnancy has not been established. Therefore, the preparation is not recommended for the treatment of women of childbearing potential, unless the burned a r e a covers more than 20 percent of the total body surface a r e a or the need for therapeutic benefit of SILVADENE Cream is, in the physician's judgment, greater than the possible risk to the fetus. Fungal colonization in and below the eschar m a y occur concomitantly with reduction of bacterial growth in the burn wound. However, fungal dissemination is rare, In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentration may approach adult therapeutic levels (8-12 mg%). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals, Precautions: If hepatic and renal functions become impaired and elimination of drugdecreases, accumulation may occur and discontinuation of SILVADENE Cream should be w e i g h e d against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with SILVADENE Cream, the possibility should be noted that silver m a y inactivate such enzymes. Adverse Reactions: It is frequently difficult to distinguish between an adverse reaction due to SILVADENE Cream (silver sulfadiazine) and reactions that may occur due to the concomitant use of other therapeutic agents used in t h a t r e a t m e n t of a patient having a severe burn wound. In the a g g r e g a t e of 2,297 patients treated with SILVADENE Cream, there w e r e 59 drug-related reactions (2.5%). Of these there w e r e 51 cases of burning, 5 of rash, 2 of itching, and 1 of interstitial nephritis. However, SILVADENE Cream therapy was discontinued in only 0.9% of the patient population. Since significant quantities of silver sulfadiazine are absorbed, it is possible that any of the adverse reactions attributable to sulfonamides may occur.
~
WOUND CARE DIVISION
MARION
LABORATORIES, INC. KANSAS CITY, MO 64137
Consult full product disclosure before prescribing. 0041M6
-N
Universi Association for Emergency Medicine
CALL FOR ABSTRACTS 18th Annual Meeting Cincinnati, Ohio May 24-26, 1988 Annual Meeting Abstract Information
P l ease read carefully f o r details a n d instructions. T h e 18th A n n u a l M e e t i n g of t h e U n i v e r s i t y A s s o c i a t i o n for E m e r g e n c y M e d i c i n e will be held May 24-26, 1988, at t h e N e t h e r l a n d Plaza Hotel in C i n c i n n a t i , Ohio. J e r r i s R Hedges, MD, P r o g r a m C h a i r m a n , is n o w a c c e p t i n g abs t r a c t s for review for oral a n d p o s t e r p r e s e n t a t i o n at t h e 1988 A n n u a l Meeting. B e c a u s e of t h e large n u m b e r of previous abstract submissions, the Annual Meeting P r o g r a m C o m m i t t e e h a s developed a two-page a b s t r a c t form to be u s e d for all a b s t r a c t s u b m i s s i o n s . T h i s form will b e i n c l u d e d in t h e D e c e m b e r 1987 i s s u e of Annals of Emergency Medicine a n d also is available u p o n req u e s t from UAEM. All a b s t r a c t s m u s t be s u b m i t t e d o n t h e o f f i c i a l abs t r a c t f o r m a n d m u s t b e r e c e i v e d b y U A E M or p o s t m a r k e d n o later t h a n F e b r u a r y 1, 1988. A b s t r a c t s n o t s u b m i t t e d o n t h e official a b s t r a c t f o r m w i l l b e r e t u r n e d to t h e a u t h o r s for r e s u b m i s s i o n . Mail e i g h t c o p i e s o f t h e c o m p l e t e d a b s t r a c t f o r m to UAEM 18th A n n u a l M e e t i n g , 9 0 0 W e s t Ottawa, L a n s i n g , M i c h i g a n 4 8 9 1 5 . Call 5 1 7 / 4 8 5 - 5 4 8 4 to o b t a i n m o r e i n f o r m a t i o n or an official a b s t r a c t form.
A b s t r a c t s s u b m i t t e d or t h e r e s u l t a n t m a n u s c r i p t s m u s t n o t a p p e a r in a refereed j o u r n a l p r i o r to p u b l i c a t i o n of t h e m e e t i n g a b s t r a c t s in t h e April 1988 i s s u e of Annals of Emergency Medicine a n d m u s t n o t have been presented previously at a national meeting. Annals of Emergency Medicine is t h e official j o u r n a l of t h e U n i v e r s i t y A s s o c i a t i o n for E m e r g e n c y M e d i c i n e . UAEM s t r o n g l y r e c o m m e n d s t h a t a u t h o r s s u b m i t t h e i r m a n u s c r i p t s to Annals. Annals will notify a u t h o r s of a d e c i s i o n r e g a r d i n g p u b l i c a t i o n w i t h i n 90 d a y s of receipt. C a s h a w a r d s will be given for t h e Best Clinical P a p e r ( H u m a n Subjects), t h e B e s t Basic S c i e n c e Paper, t h e Best Poster, a n d t h e Best R e s i d e n t Poster. A n a w a r d will be given byAnnals of Emergency Medicine for t h e B e s t R e s i d e n t P a p e r p u b l i s h e d in Annals. All a w a r d w i n n e r s will b e a n n o u n c e d at t h e 19th A n n u a l Meeting, May 30J u n e 1, 1989, in S a n Diego, California.
SILVADENE®CREAM (1% silver sulfadiazine)
Each gram of SILVADENE Cream contains 10 m g of micronized silver sulfadiazine. The cream vehicle consists of white petrolatum, stearyl alcohol, isopropyl myristate, sorbitan monooleate, polyoxyl 40 stearate, propylene glycol, and water, with methylparaben 0.3% as a preservative. Indications: Topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. C o n t r a i a d i c a t i o n s : Because sulfonamide therapy is known to increase the possibility of kernicterus, SILVADENE Cream should not be used at term pregnancy, on premature infants, or on newborn infants during the first month of life. Warnings: SILVADENE Cream should be administered with great caution to patients with history of hypersensitivity to SILVADENE Cream. It is not known whether there is cross-sensitivity to other sulfonamides. If allergic reactions attributable to treatment with SILVADENE Cream occur, discontinuation of SILVADENE Cream must be considered. The use of SILVADENE Cream in some cases of glucose-6-phosphate dehydrogenase deficient individuals may be hazardous, as hemolysis may occur. USE IN PREGNANCY. Safe use of SILVADENE Cream during pregnancy has not been established. Therefore, the preparation is not recommended for the treatment of women of childbearing potential, unless the burned a r e a covers more than 20 percent of the total body surface a r e a or the need for therapeutic benefit of SILVADENE Cream is, in the physician's judgment, greater than the possible risk to the fetus. Fungal colonization in and below the eschar m a y occur concomitantly with reduction of bacterial growth in the burn wound. However, fungal dissemination is rare, In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentration may approach adult therapeutic levels (8-12 mg%). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals, Precautions: If hepatic and renal functions become impaired and elimination of drugdecreases, accumulation may occur and discontinuation of SILVADENE Cream should be w e i g h e d against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with SILVADENE Cream, the possibility should be noted that silver m a y inactivate such enzymes. Adverse Reactions: It is frequently difficult to distinguish between an adverse reaction due to SILVADENE Cream (silver sulfadiazine) and reactions that may occur due to the concomitant use of other therapeutic agents used in t h a t r e a t m e n t of a patient having a severe burn wound. In the a g g r e g a t e of 2,297 patients treated with SILVADENE Cream, there w e r e 59 drug-related reactions (2.5%). Of these there w e r e 51 cases of burning, 5 of rash, 2 of itching, and 1 of interstitial nephritis. However, SILVADENE Cream therapy was discontinued in only 0.9% of the patient population. Since significant quantities of silver sulfadiazine are absorbed, it is possible that any of the adverse reactions attributable to sulfonamides may occur.
~
WOUND CARE DIVISION
MARION
LABORATORIES, INC. KANSAS CITY, MO 64137
Consult full product disclosure before prescribing. 0041M6
-N
Universi Association for Emergency Medicine
CALL FOR ABSTRACTS 18th Annual Meeting Cincinnati, Ohio May 24-26, 1988 Annual Meeting Abstract Information
P l ease read carefully f o r details a n d instructions. T h e 18th A n n u a l M e e t i n g of t h e U n i v e r s i t y A s s o c i a t i o n for E m e r g e n c y M e d i c i n e will be held May 24-26, 1988, at t h e N e t h e r l a n d Plaza Hotel in C i n c i n n a t i , Ohio. J e r r i s R Hedges, MD, P r o g r a m C h a i r m a n , is n o w a c c e p t i n g abs t r a c t s for review for oral a n d p o s t e r p r e s e n t a t i o n at t h e 1988 A n n u a l Meeting. B e c a u s e of t h e large n u m b e r of previous abstract submissions, the Annual Meeting P r o g r a m C o m m i t t e e h a s developed a two-page a b s t r a c t form to be u s e d for all a b s t r a c t s u b m i s s i o n s . T h i s form will b e i n c l u d e d in t h e D e c e m b e r 1987 i s s u e of Annals of Emergency Medicine a n d also is available u p o n req u e s t from UAEM. All a b s t r a c t s m u s t be s u b m i t t e d o n t h e o f f i c i a l abs t r a c t f o r m a n d m u s t b e r e c e i v e d b y U A E M or p o s t m a r k e d n o later t h a n F e b r u a r y 1, 1988. A b s t r a c t s n o t s u b m i t t e d o n t h e official a b s t r a c t f o r m w i l l b e r e t u r n e d to t h e a u t h o r s for r e s u b m i s s i o n . Mail e i g h t c o p i e s o f t h e c o m p l e t e d a b s t r a c t f o r m to UAEM 18th A n n u a l M e e t i n g , 9 0 0 W e s t Ottawa, L a n s i n g , M i c h i g a n 4 8 9 1 5 . Call 5 1 7 / 4 8 5 - 5 4 8 4 to o b t a i n m o r e i n f o r m a t i o n or an official a b s t r a c t form.
A b s t r a c t s s u b m i t t e d or t h e r e s u l t a n t m a n u s c r i p t s m u s t n o t a p p e a r in a refereed j o u r n a l p r i o r to p u b l i c a t i o n of t h e m e e t i n g a b s t r a c t s in t h e April 1988 i s s u e of Annals of Emergency Medicine a n d m u s t n o t have been presented previously at a national meeting. Annals of Emergency Medicine is t h e official j o u r n a l of t h e U n i v e r s i t y A s s o c i a t i o n for E m e r g e n c y M e d i c i n e . UAEM s t r o n g l y r e c o m m e n d s t h a t a u t h o r s s u b m i t t h e i r m a n u s c r i p t s to Annals. Annals will notify a u t h o r s of a d e c i s i o n r e g a r d i n g p u b l i c a t i o n w i t h i n 90 d a y s of receipt. C a s h a w a r d s will be given for t h e Best Clinical P a p e r ( H u m a n Subjects), t h e B e s t Basic S c i e n c e Paper, t h e Best Poster, a n d t h e Best R e s i d e n t Poster. A n a w a r d will be given byAnnals of Emergency Medicine for t h e B e s t R e s i d e n t P a p e r p u b l i s h e d in Annals. All a w a r d w i n n e r s will b e a n n o u n c e d at t h e 19th A n n u a l Meeting, May 30J u n e 1, 1989, in S a n Diego, California.